Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
175 hedge funds and large institutions have $2.8B invested in Apellis Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 53 increasing their positions, 62 reducing their positions, and 21 closing their positions.
218% more call options, than puts
Call options by funds: $24.1M | Put options by funds: $7.55M
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
4% more funds holding
Funds holding: 168 → 175 (+7)
3.43% less ownership
Funds ownership: 84.36% → 80.92% (-3.4%)
15% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 62
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
23% less capital invested
Capital invested by funds: $3.65B → $2.8B (-$856M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$47.3M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$36.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$28.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$65.5M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$44.3M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$22.3M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$17.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$11M |
APLS Hedge Fund Activity: Q1 2021 in Review
175 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2021, worth a combined $2.8B — down 23% from $3.65B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new APLS positions and 21 closed out — a net gain of 8 holders — while 53 added to existing stakes and 62 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $47.3M. The largest seller was Citadel Advisors, cutting an estimated $65.5M.
- 175 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2021, up from 168 in Q4 2020.
- Funds reported $2.8B of Apellis Pharmaceuticals stock for Q1 2021, down 23% quarter-over-quarter.
- 29 funds opened new Apellis Pharmaceuticals positions in Q1 2021 and 21 closed out, a net change of +8 holders.
- The largest Apellis Pharmaceuticals buyer in Q1 2021 was Avoro Capital Advisors, an estimated $47.3M added.
- The largest Apellis Pharmaceuticals seller in Q1 2021 was Citadel Advisors, an estimated $65.5M sold.
Based on aggregated 13F filings for Q1 2021.